SGLT2 inhibitors are an addition to our pharmacotherapy toolkit that have cardio- and kidney-protective benefits for individuals with kidney disease. New information from clinical trials has prompted guideline updates from leading diabetes and nephrology organizations. In this module, we will review the supporting evidence and guidelines in addition to discussing clinical considerations for the optimal use of SGLT inhibitors in improving cardiometabolic and kidney outcomes.
Katherine H. Cho, PharmD, BCACP
Clinical Assistant Professor, Temple University School of Pharmacy
Dr. Katherine H. Cho is a Clinical Assistant Professor of Ambulatory Care at Temple University School of Pharmacy. After finishing her Doctor of Pharmacy training at the University of Michigan, she completed pharmacy residencies and fellowship at the University of Pittsburgh and the University of Michigan. In addition to didactic and experiential teaching, Dr. Cho currently practices in outpatient Internal Medicine at Temple General Internal Medicine under a collaborative practice agreement with diabetes, hypertension, and dyslipidemia. She also has experience practicing in multidisciplinary nephrology and outpatient hemodialysis clinics and is actively involved in pharmacy and multidisciplinary professional organizations.
